Amino-tetrazoles analogues and methods of use

1. A method for treating chronic inflammatory pain or neuropathic pain comprising administering to a patient in need of such treatment a pharmaceutical composition comprising a compound having Formula (I) or Formula (II),

or a therapeutically acceptable salt thereof, in which

R 2 is phenyl or pyridyl, in which each R 2 is substituted with one, two, three, four, or five substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NH 2 , —R 2a , —OR 2 , —NHR 2a , —N(R 2a ) 2 , —CN, —SR 2a , and —SO 2 R 2a ;

R 2a is —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 2b ;

R 2b is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —Br, —I, —F, —Cl, —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —NH 2 , —NHR 2c , —N(R 2c ) 2 , —CN, —SR 2c , and —SO 2 R 2c ;

R 2c is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

m is 0, 1, 2, or 3;

X and Y are independently selected from the group consisting of —H, —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, and —C 6 -alkyl; or

X and Y together with the carbon atom to which they are attached form a ring selected from the group consisting of cyclopropane, cyclobutane, cyclopentane, cyclohexane, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, dioxolane, tetrahydropyran, piperidine, morpholine, thiomorpholine, and piperazine, each or which is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NH 2 , —R 2a , —OR 2a , —NHR 2a , —N(R 2a ) 2 , —CN, —SR 2a , and —SO 2 R 2a ;

Z is —H, —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or C 6 -alkyl; or

Z and X together with the atoms to which they are attached form a ring selected from the group consisting of pyrrolidine, piperidine, morpholine, thiomorpholine, and piperazine;

R 1 is selected from the group consisting of:

(a) phenyl which is unfused or fused with a ring selected from the group consisting of cyclopentane, cyclohexane, cyclopentene, cyclohexene, dioxane, dioxolane, naphthalene, benzene, furan, imidazole, isothiazole, oxazole, isoxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, tetrahydrofuran, tetrahydrothiophene, thiazole, thiophene, pyrrolidine, dioxolane, pyrazolidine, pyran, piperidine, morpholine, thiomorpholine, oxazolidinone, morpholinone, and piperazine, wherein the phenyl and each ring optionally fused thereto are, independently of each other, unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —OH, —NH 2 , —NO 2 , —R 1a , —OR 1a , —NHR 1a , —N(R 1a ) 2 , —CN, —SR 1a , —SO 2 R 1a , —SO 2 NH 2 , —SO 2 N(H)(R 1a ), —SO 2 N(R 1a ) 2 , —C(O)R 1d , —C(O)OR 1a , —C(O)NH 2 , —C(O)N(H)(R 1a ), —C(O)N(R 1a ) 2 , —OR 1e , —SR 1e , —SO 2 R 1e , —SO 2 N(H)(R 1e ) —SO 2 N(R 1d )(R 1e ), —NH(R 1e ), —N(R 1d )(R 1e ), —NHC(O)R 1f , —N(R 1d )C(O)R 1f , and —R 1c ;

(b) isoxazolyl, oxazolyl, pyrrolidinyl, pyridyl, thienyl, pyrrolyl, pyridazinyl, pyrazolyl, imidazolyl, thiazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, pyrimidinyl, pyrazinyl, or imidazopyridinyl, each of which is unfused or fused with a ring selected from the group consisting of cyclopentane, cyclohexane, cyclopentene, cyclohexene, naphthalene, benzene, furan, imidazole, isothiazole, oxazole, isoxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, tetrahydrofuran, tetrahydrothiophene, thiazole, thiophene, pyrrolidine, dioxolane, pyrazolidine, pyran, piperidine, morpholine, thiomorpholine, and piperazine, ring, in which each of the pyrrolidinyl, pyridyl, thienyl, pyrrolyl, pyridazinyl, pyrazolyl, imidazolyl, thiazolyl, furyl, tetrahydrofuryl, pyrimidinyl, pyrazinyl, or imidazopyridinyl ring and each ring optionally fused thereto are, independently of each other, unsubstituted or substituted with one, two, three, or four substitutents independently selected from the group consisting of —Cl, —F, —Br, —I, —OH, —NH 2 , —NO 2 , —R 1a , —OR 1a , —NHR 1a , —N(R 1a ) 2 —CN, —SR 1a , —SO 2 R 1a , —SO 2 NH 2 , —SO 2 N(H)(R 1a ), —SO 2 N(R 1a ) 2 , —C(O)R 1a , —C(O)OH, —C(O)OR 1a , —C(O)NH 2 , —C(O)N(H)(R 1a ), —C(O)N( 1a ) 2 , —OR 1e , —SR 1e , —SO 2 R 1e , —SO 2 N(H)(R 1e ), —SO 2 N(R 1d )(R 1e )—NH(R 1e ), —N(R 1d )(R 1e ), —NHC(O)R 1f , —N(R 1d )C(O)R 1f , and —R 1e ,

(c) bicyclo[2,2,1]heptyl, cyclopentyl, cyclohexyl, cyclopentenyl, or cyclohexenyl, each of which is unfused or fused with a cyclopentane, cyclohexane, cyclopentene, cyclohexene, naphthalene, benzene, furan, imidazole, isothiazole, oxazole, isoxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, imidazoline, tetrahydrofuran, tetrahydrothiophene, thiazole, thiophene, pyrrolidine, dioxolane, pyrazoline, pyrazolidine, pyran, piperidine, morpholine, thiomorpholine, or piperazine ring, in which each of the cyclopentyl, cyclohexyl, cyclopentenyl, or cyclohexenyl ring and each ring optionally fused thereto are, independently of each other, unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of ═O, —Cl, —F, —Br, —I, —OH, —NH 2 , —NO 2 , —R 1a , —OR 1a , —NHR 1a , —N(R 1a ) 2 , —CN, —SR 1a , —SO 2 R 1a , —SO 2 NH 2 , —SO 2 N(H)(R 1a ), —SO 2N(R 1a ) 2 , —C(O)R 1a , —C(O)OH, —C(O)OR 1a , —C(O)NH 2 , —C(O)N(H)(R 1e ), —C(O)N(R 1a ) 2, —OR 1e , —SR 1e , —SO 2 R 1e , —SO 2 N(H)R 1e ), —SO 2 N(R 1d )(R 1e ), —NH(R 1e ), —N(R 1d )(R 1e ), —NHC(O)R 1f , —N(R 1d )C(O)R 1f , and —R 1c ;

(d) admantyl unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NO 2 , —OH, —NH 2 , —R 1d , —OR 1d , —NHR 1d , —N(R 1d ) 2 , —CN, —SR 1d , —SO 2 R 1d , —SO 2 NH 2 , —SO 2 N(H)(R 1d ), —SO 2 N(R 1d ) 2 , —C(O)R 1d , —COOH, —C(O)OR 1d , —C(O)NH 2 , —C(O)N(H)(R 1d ), and —C(O)N(R 1d ) 2 ; and

(e) 2,3-dihydrospiroindene-1,4′-piperidinyl unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NO 2 , —OH, —NH 2 , —R 1d , —OR 1d , —NHR 1d , —N(R 1d ) 2 , —CN, —SR 1d , —SO 2 R 1d , —SO 2 NH 2 , —SO 2 N(H)(R 1d ), —SO 2 N(R 1d ) 2 , —C(O)R 1d , —COOH, —C(O)OR 1d , —C(O)NH 2 , —C(O)N(H)(R 1d ), and —C(O)N)R 1d ) 2 ;

R 1a is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 1b ;

R 1b is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —F, —Cl, —Br, —I, —NH 2 , —OH, —OR 1d , —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, —R 1c , —N(R 1d ) 2 , and —NHR 1d ;

R 1c is cycloalkyl, cycloalkenyl, aryl, heteroaryl or heterocycle, in which each R 1c is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of ═O, —Cl, —F, —Br, —I, —NO 2 , —CN, —OH, R 1aa , —NH 2 , —OR 1aa , —SR 1aa , —NHR 1aa , —N(R 1aa ) 2 , C(O)R 1aa , —S(O) 2 R 1aa , —S(O) 2 NH 2 , —S(O) 2 N(R 1aa ) 2 , —C(O)NH 2 , —C(O)N(H)(R 1aa ), —C(O)N(R 1aa ) 2 , —C(O)OH, —C(O)OR 1aa , —OR 1h , —N(H)R 1h , —N(R 1d )(R 1h ) and —R 1h ;

R 1aa is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 1bb ;

R 1bb is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —F, —Cl, —Br, —I, —NO 2 , —CN, haloalkyl, haloalkoxy, —NH 2 , —OH, —OR 1d , —SR 1d , —S(O) 2 R 1d , —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, —N(R 1d ) 2 , —NHR 1d , —C(O)OH, —C(O)OR 1d , —C(O)NH 2 , —C(O)N(H)(R 1d ), —C(O)N(R 1d ) 2 , —S(O) 2 NH 2 , —S(O) 2 N(H)(R 1d ), —S(O) 2 N(R 1d ) 2 and —R 1h ;

R 1d is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

R 1e is a monocyclic or bicyclic ring selected from the group consisting of cycloalkyl, heterocycle, aryl and heteroaryl, wherein each ring is unsubstituted or substituted with one, two, three or four substituents independently selected from the group consisting of ═O, —Cl, —F, —Br, —I, —NO 2 , —CN, —OH, —R 1aa , —OR 1aa , —SR 1aa , —NH 2 , —NHR 1aa , and N(R 1aa ) 2 ;

R 1f is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, aryl, heteroaryl, —R 1h , or

R 1g is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one substituent selected from the group consisting —R 1h ;R 1h is cycloalkyl, cycloalkenyl, aryl, heteroaryl or heterocycle, in which each R 1h is unsubstituted or substituted with one or two or three or four or five substituents independently selected from the group consisting of —F, —Cl, —Br, —I, —NO 2 , —CN, haloalkyl, haloalkoxy, —NH 2 , —OH, —OR 1d , —SR 1d , —S(O) 2 R 1d , —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, —N(R 1d ) 2 , —NHR 1d , —C(O)OH, —C(O)OR 1d , —C(O)NH 2 , —C(O)N(H)(R 1d ), —C(O)N(R 1d ) 2 , —S(O) 2 NH 2 , —S(O) 2 N(H)(R 1d ), and —S(O) 2 N(R 1d ) 2 ;

provided that when R 1 is phenyl fused with a pyrrole, thiophene, furan, pyrazole, isoxazole, or isothiazole ring, the pyrrole, thiophene, furan, pyrazole, isoxazole, or isothiazole ring is not substituted with —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, pyrrolidinyl, piperidyl, tetrahydropyridyl, pyrrolinyl, —C 1 -alkyl substituted with pyrrolidinyl or piperidyl, —C 2 -alkyl substituted with —N(R 1d ) 2 , —NH 2 or —NHR 1d , —C 3 -alkyl substituted with —N(R 1d ) 2 , —NH 2 , or —NHR 1d , —C 4 -alkyl substituted with —N(R 1d ) 2 , —NH 2 , or —NHR 1d , —C 5 -alkyl substituted with —N(R 1d ) 2 , —NH 2 , or —NHR 1d , or —C 6 -alkyl substituted with —N(R 1d ) 2 , —NH 2 , or —NHR 1d ;

and provided that when m is 0 and R 2 is phenyl, then R 1 is not unfused phenyl;

A is N or CR 6 ;

B is N or CR 7 ;

B is N or CR 8 ;

provided that only one of A, B and E is N;

R 3 is —NH 2 , —R 3a , —OR 3a , —NHR 3a , —N(R 3a ) 2 , NHC(O)R 3f , —N(R 3d )C(O)R 3f , —R 3c , —OR 3e , —SR 3e , —NH(R e ), or —N(R 3d )(R 3e );

R 3a is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 3b ;

R 3b is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —NH 2 , —CN, —OH, —OR 3d , R 3c , —N(R 3d ) 2 , and —NHR 3d ;

R 3c is cycloalkyl, cycloalkenyl, aryl, heteroaryl or heterocycle, in which each R 3c is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —OH, —R 3aa , —NH 2 , —OR 3aa , —SR 3aa , —NHR 3aa , and —N(R 3aa ) 2 ;

R 3d is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

R 3aa is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 3bb ;

R 3bb is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —F, —Cl, —Br, —I, —NH 2 , —OH, —OR 3d , —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, —N(R 3d ) 2 , and —NHR 3d ;

R 3e is a monocyclic or bicyclic ring selected from the group consisting of cycloalkyl, heterocycle, aryl and heteroaryl, in which each ring is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of ═O, —Cl, —F, —Br, —I, —OH, —R 3aa , —NH 2 , —OR 3aa , SR 3aa , —NHR 3aa , and —N(R 3aa ) 2 ;

R 3f is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, aryl, heteroaryl, or R 3g ;

R 3g is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one substituent selected from the group consisting of aryl and heteroaryl;

v is one, two, or three, and when v is two or three, R 3 may be the same or different;

R 4 is —Cl, —F, —Br, —I, —NH 2 , —R 4a , —OR 4a , —NHR 4a , N(R 4a ) 2 , —CN, —SR 4a or —SO 2 R 4a ;

R 4a is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 3 -alkyl, —C 6 -alkyl, or R 4b ;

R 4b is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —Br; —I, —F, —Cl, —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —NH 2 , —NHR 4c , —N(R 4c ) 2 , —CN, —SR 4c , and —SO 2 R 4c ;

R 4c is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

R 5 is —H, —Cl, —F, —Br; —I, —NH 2 , —R 5a , —OR 5a , —NHR 5a , —N(R 5a ) 2 , —CN, —SR 5a , or —SO 2 R 5a ;

R 5a is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 5b ;

R 5b is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 6 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —Br; —I, —F, —Cl, —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —NH 2 , —NHR 5c , —N(R 5c ) 2 , —CN, —SR 5c , and —SO 2 R 5c ;

R 5c is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

R 6 is —H, —Cl, —F, —Br; —I, —NH 2 , —R 6a , —OR 6a , —NHR 6a , —N(R 6a ), —CN, —SR 6a or —SO 2 R 6a ;

R 6a is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 6b ;

R 6b is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —Br; —I, —F, —Cl, —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —NH 2 , —NHR 6c , —N(R 6c ) 2 , —CN, —SR 6c , and —SO 2 R 6c ;

R 6c is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

R 7 is —H, —Cl, —F, —Br; —I, —NH 2 , R 7a , —OR 7a , —NHR 7a , —N(R 7a ) 2 , —CN, —SR 7a , or —SO 2 R 7a ;

R 7a is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 7b ;

R 7b is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —Br; —I, —F, —Cl, —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —NH 2 , —NHR 7c , —N(R 7c ) 2 , —CN, —SR 7c , and —SO 2 R 7c ;

R 7c is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

R 8 is —H, —Cl, —F, —Br; —I, —NH 2 , —R 8a , —OR 8a , —NHR 8a , —N(R 8a ) 2 , —CN, —SR 8a or —SO 2 R 8a ;

R 8a is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 8b ;

R 8b is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —Br, —I, —F, —Cl, —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —NH 2 , —NHR 8c , —N(R 8c ) 2 , —CN, —SR 8c , and —SO 2 R 8c ;

R 8c is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl; and

with the proviso that the following compounds are excluded:

N-benzyl-1-(4-methoxyphenyl)-1H-tetraazol-5-amine;

N,1-bis(4-methylphenyl)-1H-tetraazol-5-amine;

N,1-bis(4-methoxyphenyl)-1H-tetraazol-5-amine; and

N,1-bis(2,4-dimethylphenyl)-1H-tetraazol-5-amine.

2. A method for treating, chronic inflammatory pain; or neuropathic pain comprising administering to a patient in need of such treatment a pharmaceutical composition comprising a compound having Formula (I),

or a therapeutically acceptable salt thereof, in which

R 2 is phenyl or pyridyl, wherein each R 2 is substituted with one, two, three, four, or five substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NH 2 , —R 2a , —OR 2a , —NHR 2a , —N(R 2a ) 2 , —CN, —SR 2a , and —SO 2 R 2a ;

R 2a is —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 2b ;

R 2b is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —Br, —I, —F, —Cl, —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —NH 2 , —NHR 2c , —N(R 2c ) 2 , —CN, —SR 2c , and —SO 2 R 2c ;

R 2c is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

m is 0, 1, 2, or 3;

X and Y are independently selected from the group consisting of —H, —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, and —C 6 -alkyl; or

X and Y together with the carbon atom to which they are attached form a ring selected from the group consisting of cyclopropane, cyclobutane, cyclopentane, cyclohexane, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, dioxolane, tetrahydropyran, piperidine, morpholine, thiomorpholine, and piperazine, each or which is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NH 2 , —R 2a , —OR 2a , —NHR 2a , —N(R 2a ) 2 , —CN, —SR 2a , and —SO 2 R 2a ;

Z is —H, —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl; or

Z and X together with the atoms to which they are attached form a ring selected from the group consisting of pyrrolidine, piperidine, morpholine, thiomorpholine, and piperazine;

R 1 is selected from the group consisting of:

(a) phenyl which is unfused or fused with a ring selected from the group consisting of cyclopentane, cyclohexane, cyclopentene, cyclohexene, dioxane, dioxolane, naphthalene, benzene, furan, imidazole, isothiazole, oxazole, isoxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, tetrahydrofuran, tetrahydrothiophene, thiazole, thiophene, pyrrolidine, dioxolane, pyrazolidine, pyran, piperidine, morpholine, thiomorpholine, oxazolidinone, morpholinone, and piperazine, wherein the phenyl and each ring optionally fused thereto are, independently of each other, unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —OH, —NH 2 , —NO 2 , —R 1a , —OR 1a , —NHR 1a , —N(R 1a ) 2 , —CN, —SR 1a , —SO 2 R 1a , —SO 2 NH 2 , —SO 2 N(H)(R 1a ), —SO 2 N(R 1a ) 2 , —C(O)R 1d , —C(O)OH, —C(O)OR 1a , —C(O)NH 2 , —C(O)N(H)(R 1a ), —C(O)N(R 1a ) 2 , —OR 1e , —SR 1e , —SO 2 R 1e , —SO 2 N(H)(R 1e ), —SO 2 N(R 1d )(R 1e ), —NH(R 1e ), —N(R 1d )(R 1e ), —NHC(O)R 1f , —N(R 1d )C(O)R 1f , and —R 1c ;

(b) isoxazolyl, oxazolyl, pyrrolidinyl, pyridyl, thienyl, pyrrolyl, pyridazinyl, pyrazolyl, imidazolyl, thiazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, pyrimidinyl, pyrazinyl, or imidazopyridinyl, each of which is unfused or fused with a cyclopentane, cyclohexane, cyclopentene, cyclohexene, naphthalene, benzene, furan, imidazole, isothiazole, oxazole, isoxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, tetrahydrofuran, tetrahydrothiophene, thiazole, thiophene, pyrrolidine, dioxolane, pyrazolidine, pyran, piperidine, morpholine, thiomorpholine, or piperazine ring, in which each of the pyrrolidinyl, pyridyl, thienyl, pyrrolyl, pyridazinyl, pyrazolyl, imidazolyl, thiazolyl, furyl, tetrahydrofuryl, pyrimidinyl, pyrazinyl, or imidazopyridinyl ring and each ring optionally fused thereto are, independently of each other, unsubstituted or substituted with one, two, three, or four substitutents independently selected from the group consisting of —Cl, —F, —Br, —I, —NO 2 , —OH, —NH 2 , —R 1a , —OR 1a , —NHR 1a , —N(R 1a ) 2 , —CN, —SR 1a , —SO 2 R 1a , —SO 2 NH 2 , —SO 2 N(H)(R 1a ), —SO 2 N(R 1a ) 2 , —C(O)R 1a , —C(O)OH, —C(O)OR 1a , —C(O)NH 2 , —C(O)N(H)(R 1a ), —C(O)N(R 1a ) 2 , —OR 1e , —SR 1e , —SO 2 R 1e , —SO 2 N(H)(R 1e ), —SO 2 N(R 1d )(R 1e ), —NH(R 1e ), —N(R 1d )(R 1e ), —NHC(O)R 1f , —N(R 1d )C(O)R 1f , and R 1c ;

(c) bicyclo[2,2,1]heptyl, cyclopentyl, cyclohexyl, cyclopentenyl, or cyclohexenyl, each of which is unfused or fused with a cyclopentane, cyclohexane, cyclopentene, cyclohexene, naphthalene, benzene, furan, imidazole, isothiazole, oxazole, isoxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, imidazoline, tetrahydrofuran, tetrahydrothiophene, thiazole, thiophene, pyrrolidine, dioxolane, pyrazoline, pyrazolidine, pyran, piperidine, morpholine, thiomorpholine, or piperazine ring, in which the cyclopentyl, cyclohexyl, cyclopentenyl, or cyclohexenyl ring and each ring optionally fused thereto are, independently of each other, unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of ═O, —Cl, —F, —Br, —I, —NO 2 , —OH, —NH 2 , R 1a , —OR 1a , —NHR 1a , —N(R 1a ) 2 , —CN, —SR 1a , —SO 2 R 1a , —SO 2 NH 2 , —SO 2 N(H)(R 1a ), —SO 2 N 1a ) 2 , —C(O)R 1a , —C(O)OH, —C(O)OR 1a , —C(O)NH 2 , —C(O)N(H)(R 1a ), —C(O)N(R 1a ) 2 , —OR 1e , —SR 1e , —SO 2 R 1e , —SO 2 N(H)(R 1e ), —SO 2 N(R 1d )(R 1e ), —NH(R 1e ), —N(R 1d )(R 1e ), —NHC(O)R 1f , —N(R 1d )C(O)R 1f , and R 1c ;

(d) admantyl unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NO 2 , —OH, —NH 2 , —R 1d , —OR 1d , —NHR 1d , —N(R 1d ) 2 , —CN, —SR 1d , —SO 2 R 1d , —SO 2 NH 2 , —SO 2 N(H)(R 1d ), —SO 2 N(R 1d ) 2 , —C(O)R 1d , —COOH, —C(O)OR 1d , —C(O)NH 2 , —C(O)N(H)(R 1d ), and —C(O)N(R 1d ) 2 ; and

(e) 2,3-dihydrospiroindene-1,4′-piperidinyl unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NO 2 , —OH, —NH 2 , —R 1d , —OR 1d , —NHR 1d , —N(R 1d ) 2 , —CN, —SR 1d , —SO 2 R 1d , —SO 2 NH 2 , —SO 2 N(H)(R 1d ), —SO 2 N(R 1d ) 2 , —C(O)R 1d , —COOH, —C(O)OR 1d , —C(O)NH 2 , —C(O)N(H)(R 1d ), and —C(O)N(R 1d ) 2 ;

R 1a is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 1b ;

R 1b is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —F, —Cl, —Br, —I, —NH 2 , —OH, —OR 1d , —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, R 1c , —N(R 1d ) 2 , and —NHR 1d ;

R 1c is cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, azetidinyl, naphthyl, quninolinyl, isoquinolinyl, phenyl, furyl, imidazolyl, isotbiazolyl, oxazolyl, oxazolinyl, isoxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, imidazolinyl, tetrahydrofuryl, tetrahydrotbienyl thiazolyl, thienyl, pyrrolidinyl, dioxolanyl, pyrazolinyl, pyrazolidinyl, pyranyl, piperidyl, morpholinyl, thiomorpholinyl, piperazinyl, 2-azabicyclo[2.2.2]octyl, 2-oxa-5-azabicyclo[2.2.2]octyl, 2,5-diazabicyclo[2.2.2]octyl, 2-azabicyclo[2.2.1]heptyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-azabicyclo[2.1.1]hexyl, 5-azabicyclo[2.1.1]hexyl, 3-azabicyclo[3.2.1]heptyl, 3,6-diazabicyclo[3.2.0]heptyl, octahydrocyclopenta[c]pyrrolyl, hexahydro-1H-furo[3,4-c]pyrrolyl, octahydropyrrolo[3,4-c]pyrrolyl, 3-azabicyclo[3.1.1]heptyl, 6-oxa-3-azabicyclo[3.1.1]heptyl, octahydro-1H-4,7-methanoisoindolyl, octahydro-1H-4,7-epoxyisoindolyl, 8-azabicyclo[3.2.1]octyl, 3-oxa-8-azabicyclo[3.2.1]octyl, 1,4-diazepanyl, 1,4-diazabicyclo[3.2.2]nonyl, 1,4-diazatricyclo[4.3.1.1 3,8 ]undecyl, 3,10-diazabicyclo[4.3.1]decyl, or 8-oxa-3-azabicyclo[3.2.1]octyl, each of which is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, ═O, —NO 2 , —CN, —OH, —R 1aa , —NH 2 , —OR 1aa , —SR 1aa , —NHR 1aa , —N(R 1aa ) 2 , —C(O)R 1aa , S(O) 2 R 1aa , S(O) 2 NH 2 , S(O) 2 N(R 1aa ) 2 , —C(O)NH 2 , —C(O)N(H)(R 1aa ), —C(O)N(R 1aa ) 2 , —C(O)OH, —C(O)OR 1aa , —OR 1h , —N(H)R 1h ), —N(R 1d )(R 1h ) and —R 1h ;

R 1aa is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or —R 1bb ;

R 1bb is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —F, —Cl, —Br, —I, —NO 2 , —CN, haloalkyl, haloalkoxy, —NH 2 , —OH, —OR 1d , —SR 1d , —S(O) 2 R 1d , —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, —N(R 1d ) 2 , —NHR 1d ; —C(O)OH, —C(O)OR 1d , —C(O)NH 2 , —C(O)N(H)(R 1d ), —C(O)N(R 1d ) 2 , —S(O) 2 NH 2 , —S(O) 2 N(H)(R 1d ), —S(O) 2 N(R 1d ) 2 and —R 1b ;

R 1d is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

R 1e is phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, furyl, thienyl, imidazolyl, thiazolyl, pyrrolidinyl, piperidyl, azepinyl, tetrahydrofuryl, tetrahydropyranyl or oxazolyl; wherein each R 1e is unsubstituted or substituted with one, two, three or four substituents independently selected from the group consisting of ═O, —Cl, —F, —Br, —I, —NO 2 , —CN, —OH, —R 1aa , —OR 1aa , —SR 1aa , —NH 2 , —NHR 1aa , and —N(R 1aa ) 2 ;

R 1f is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, aryl, heteroaryl, R 1h , or R 1g ;

R 1g is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one substituent selected from the group consisting of aryl and heteroaryl;

R 1h is cycloalkyl, cycloalkenyl, aryl, heteroaryl or heterocycle, in which each R 1h is unsubstituted or substituted with one or two or three or four or five substituents independently selected from the group consisting of —F, —Cl, —Br, —I, —NO 2 , —CN, haloalkyl, haloalkoxy, —NH 2 , —OH, —OR 1d , —SR 1d , —S(O) 2 R 1d , —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, ——C 6 -alkyl, —N(R 1d ) 2 , —NHR 1d , —C(O)OH, —C(O)OR 1d , —C(O)NH 2 , —C(O)N(H)(R 1d ), —C(O)N(R 1d ) 2 , —S(O) 2 NH 2 , —S(O) 2 N(H)(R 1d ), and —S(O) 2 N(R 1d ) 2 ;

provided that when R 1 is phenyl fused with a pyrrole, thiophene, furan, pyrazole, isoxazole, or isothiazole ring, the pyrrole, thiophene, furan, pyrazole, isoxazole, or isothiazole ring is not substituted with —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, pyrrolidinyl, piperidyl, —C 1 -alkyl substituted with pyrrolidinyl or piperidyl, —C 2 -alkyl substituted with —N(R 1d ) 2 , —NH 2 , or —NHR 1d , —C 3 -alkyl substituted with —N(R 1d ) 2 , —NH 2 , or —NHR 1d , —C 4 -alkyl substituted with —N(R 1d ) 2 , —NH or —NHR 1d , —C 5 -alkyl substituted with —N(R 1d ) 2 , —NH 2 , or —NHR 1d , or —C 6 -alkyl substituted with —N(R 1d ) 2 , —NH 2 , or —NHR 1d ;

and provided that when m is 0 and R 2 is phenyl, then R 1 is not unfused phenyl; and

with the proviso that the following compound is excluded:

N-benzyl-1-(4-methoxyphenyl)-1H-tetraazol-5-amine.

3. The method of claim 1 , wherein P2X 7 activity is inhibited.

4. The method of claim 2 , wherein P2X 7 activity is inhibited.